Castrate Resistant Prostate Cancer clinical trials

Explore recruiting castrate resistant prostate cancer clinical trials.

Recruiting castrate resistant prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Castrate Resistant Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE 4)

France, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Patients with Advanced Solid Tumors and Subsequent Expansion Cohorts

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment

Sweden, Netherlands, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer

Italy, Germany, Poland, France, Denmark, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

(20510) A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of androgen receptor pathway inhibitor (ARPI) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of ARPI

Italy, Poland, Lithuania, Austria, Hungary, France +4 more

Therapeutic use (Phase IV) EU CTIS Study details

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Spain, Poland, Netherlands, Italy, Germany, Ireland +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Castrate Resistant Prostate Cancer trials by city

Castrate Resistant Prostate Cancer in Toronto Castrate Resistant Prostate Cancer in Vancouver Castrate Resistant Prostate Cancer in Montreal Castrate Resistant Prostate Cancer in Calgary Castrate Resistant Prostate Cancer in Edmonton Castrate Resistant Prostate Cancer in Ottawa Castrate Resistant Prostate Cancer in Winnipeg Castrate Resistant Prostate Cancer in Quebec City Castrate Resistant Prostate Cancer in Hamilton Castrate Resistant Prostate Cancer in Kitchener Castrate Resistant Prostate Cancer in London Castrate Resistant Prostate Cancer in Halifax Castrate Resistant Prostate Cancer in New York Castrate Resistant Prostate Cancer in Los Angeles Castrate Resistant Prostate Cancer in Chicago Castrate Resistant Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease